Takeda Pharmaceuticals has acquired the global rights to develop and market the investigational oral therapy soticlestat (OV935/TAK-935) for developmental and…
Articles by Patricia Inácio, PhD
The U.S. Food and Drug Administration (FDA) has expanded the age range for all Epidiolex (cannabidiol) indications to…
Encoded Therapeutics has raised $135 million to support the first human clinical trials for ETX101, its gene therapy for…
Epidiolex (cannabidiol), as an add on-therapy administered at either a low or high dose, leads to similar clinically relevant reductions…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…
The U.S. Food and Drug Administration (FDA) extended by three months the review period for Zogenix’s…
Editor’s note: This story has been updated to add that Zogenix resubmitted a new drug application for Fintepla to the…
Neucyte and Trillium Therapeutics have established a license agreement to develop a new therapy for drug-resistant epilepsies,…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation — allowing various development incentives —…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), is recommending approval of GW Pharmaceutical’s oral…